>
For Health Centers

Make your checkups see earlier.

Pancreatic cancer AI screening is the new highlight of preventive care — from workflow integration to radiology collaboration, live in 4 weeks.

Why pancreatic AI

Why add pancreatic AI screening to your health check?

Pancreatic cancer has one of the lowest survival rates — and almost no early symptoms. Your clients need it; nobody offers it yet.

Real demand

Pancreatic cancer ranks among Taiwan's top-10 cancer killers; the high-risk population (60+, family history, diabetes, smoking) keeps growing.

A true differentiator

Beyond routine heart-lung checkups, AI pancreatic screening makes your center the place that “sees earlier.”

Proven technology

TFDA license No. 007946, FDA Breakthrough, AUC 0.95 — regulatory and literature-backed, ready to convince.

Integration

Four weeks, contract to go-live

A dedicated project manager throughout; radiologist and technologist training included.

1

Week 1 · Assessment

Review equipment (CT model, PACS version) and workflow; define report format and alert rules.

2

Week 2 · Integration

AI server setup and PACS/RIS interfacing; automatic DICOM routing; zero extra steps for radiology.

3

Week 3 · Validation & training

Validation on institutional data plus training for radiologists and technologists (online course included).

4

Week 4 · Go-live

Go-live, pilot run, performance dashboard delivered. Monthly quality reports thereafter.

Radiology workflow

Physicians decide, AI reminds

PANCREASaver® doesn't change how radiologists read — it simply adds a pair of eyes that never tire.

Scan complete

CT scan finishes; images are analyzed by AI in the background (~60–90 seconds).

AI annotation alert

Suspicious findings are flagged side-by-side with the original images for the radiologist's review.

Follow-up suggestion

For positive cases, the system suggests follow-up — no early signal slips through.

Real-world numbers

Validated in real settings

92.1%
Sensitivity (<2cm tumors)
0.95
Multi-center AUC
300+
Cases interpreted
10
Patents (TW & US)
Performance metric Value Source
Sensitivity for tumors < 2 cm92.1%Lancet Digital Health 2020 ↗
Specificity92.8%Lancet Digital Health 2020 ↗
Nationwide multi-center AUC (n=1,473)0.95Radiology 2023 ↗
Cases interpreted (incl. clinical validation)2,000+Deployment record

Want to know more? Let's talk.

Partnership, media, or careers — all welcome.

Contact Us